Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06852950

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Location status: Recruiting

Location contact

Angel Morvant, MD

CONTACT

[email protected]

(615) 343-8332

Angel Morvant, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
  • Able to give informed consent
  • Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
  • POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
  • Need glucose readings greater than or equal to one time per day
  • Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone

Exclusion criteria

  • Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
  • Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
  • Received chemotherapy during current hospitalization
  • Planning on major surgery within 10-15 days
  • Hemodialysis or peritoneal dialysis
  • Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
  • Vitamin C use of more than 500 milligrams per day
  • Hydroxyurea use
  • Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
  • Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
  • Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
  • Skin allergy to adhesives

Treatment and study plan

Libre 3 Plus Continuous Glucose Monitor

Device

Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.

Dexcom G7 Continuous Glucose Monitor

Device

Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.

Primary outcomes

  1. Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system

    Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge

    Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system: regarding how do subjects feel that using CGM impacted their glucose control on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better?; regarding what is the overall opinion of subject's experience with CGM use on a scale of 1-5, with 1=very negative, 2=negative, 3=neutral, 4=positive, 5=very positive.

  2. Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care

    Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge

    Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care: regarding how do subjects feel that using CGM impacted the diabetes care overall on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better.

  3. Questionnaire responses regarding patient familiarity with continuous glucose monitoring

    Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge

    Questionnaire responses regarding patient familiarity with continuous glucose monitoring: regarding degree of familiarity of CGMs in general and the different types of information provided by CGMs, what is the subject's familiarity on a scale of 1-5, with 1=very unfamiliar, 2=unfamiliar, 3=neutral, 4=familiar, 5=very familiar.

Secondary outcomes

  1. Degree of Average Change in Hemoglobin A1C from Start to End of Study

    Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge

    Degree of average change in Hemoglobin A1C from start to end of study

  2. Degree of Average Change in Glucose Management Indicator (GMI)

    Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge

    Degree of average change in glucose management indicator (GMI)

  3. Number of Participants with 30-day Readmissions Related to Glycemic Control

    Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge

    Number of participants with 30-day Readmissions Related to Glycemic Control (hyperglycemia, hypoglycemia, or diabetic ketoacidosis)

Study contacts

Contact information is provided by the study sponsor or research team.

Angel Morvant, MD

CONTACT

[email protected]

615-343-8332

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Feb 28, 2025
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.